36th week of 2010 patent applcation highlights part 33 |
Patent application number | Title | Published |
20100226908 | COMPOSITIONS FOR PROMOTING WOUND HEALING AND TREATING PSORIASIS - The present invention relates to compositions and methods for promoting healing of cutaneous, mucosal and/or mucocutaneous lesions associated with the presence of a mycoplasma and one or more non-mycoplasma microorganisms. The compositions and methods of the invention also relate to the reduction of joint pain, column pain, and/or skeletal muscle pain | 2010-09-09 |
20100226909 | Method And Apparatus For Producing Autologous Thrombin - A device for isolating a component of a multi-component composition. The device includes a housing, a chamber, and a withdrawal port. The chamber is rotatably mounted within the housing. The chamber includes a chamber base and a sidewall. The side wall extends from the chamber base. At least a portion of the sidewall is defined by a filter that permits passage of a first component of the multi-component composition out of the chamber through the filter and to the housing base. The filter restricts passage of a second component of the multi-component composition through the filter. The withdrawal port extends from a position proximate to the housing base to an exterior of the device. The withdrawal port permits the withdrawal of the first component from the housing base to an exterior of the device. | 2010-09-09 |
20100226910 | TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN - This invention relates to methods of treating Alzheimer's disease or symptoms thereof, and amnesic mild cognitive impairment or symptoms thereof. Methods of the invention include administering a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof. The invention further relates to uses of tissue kallikrein or a variant or active fragment thereof for the digesting or cleaving amyloid and the treatment of conditions benefiting from the digestion or cleavage of amyloid. The invention further relates to pharmaceutical compositions comprising a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof formulated for oral or intranasal administration. | 2010-09-09 |
20100226911 | Treating or preventing extracellular matrix build-up - A method of treatment for treating, preventing, inhibiting or reducing extracellular matrix build-up in a body tissue or a bodily fluid transport vessel, in a subject, includes administering to a subject in need of such treatment an effective amount of a composition including a peptide agent including amino acid sequence LKKTET, a conservative variant thereof, or a peptide agent that stimulates production of an LKKTET peptide, or a conservative variant thereof, in the tissue. | 2010-09-09 |
20100226912 | RECOMBINANT PROTEIN PRODUCTION IN AVIAN EBx.RTM. CELLS - The invention generally relates to the field of recombinant protein production. More particularly, the invention relates to the use of avian embryonic derived stem cell lines, named EBx®, for the production of proteins and more specifically glycoproteins such as antibodies. The invention is useful for the production of monoclonal IgG1 antibody subtype having high cell-mediated cytotoxic activity. The invention relates to the use of such antibodies as a drug to treat cancers and inflammatory diseases. | 2010-09-09 |
20100226913 | Therapeutic Compositions Comprising Monoterpenes - This invention provides a compositions for transport of a therapeutic agent. The compositions contain a therapeutic agent and a monoterpene or an analog thereof. In one aspect, the monoterpene is perillyl alcohol (POH) or an analog thereof. In one aspect, the therapeutic agent is provided in an amount effective to treat the disease or subject of choice. | 2010-09-09 |
20100226914 | METHOD FOR PREPARATION OF SINGLE CHAIN ANTIBODIES - This invention provides a method for identifying cells expressing a target single chain antibody (scFv) directed against a target antigen from a collection of cells that includes cells that do not express the target scFv, comprising the step of combining the collection of cells with an anti-idiotype directed to an antibody specific for the target antigen and detecting interaction, if any, of the anti-idiotype with the cells, wherein the occurrence of an interaction identifies the cell as one which expresses the target scFv. This invention also provides a method for making a single chain antibody (scFv) directed against an antigen, wherein the selection of clones is made based upon interaction of those clones with an appropriate anti-idiotype, and heretofore inaccessible scFv so made. This invention provides the above methods or any combination thereof. Finally, this invention provides various uses of these methods. | 2010-09-09 |
20100226915 | AGER-Peptides and Use Thereof - The present invention relates to the identification, functionality and use of domains from the N terminus of the receptor for Advanced Glycation End Products (AGER). These domains, called receptor mulitimerization epitope (RME), are highly conserved in all AGER protein sequences. They represent the mediators for AGER self-association and heteromerization with other proteins. The invention likewise relates to the identification, functionality and use of peptides derived from the C domain of AGER (AGER-CDP). The AGER RMEs and AGER-CDPs of the invention are suitable as target for identifying AGER ligands which modulate the natural ligand interaction; as immunogen for active or passive immunization of individuals, as diagnostic means for identifying immunogenic reactions, and as peptide ligands for modulating protein-protein interactions involving AGER. | 2010-09-09 |
20100226916 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND CONDITIONS - The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, particularly ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation, and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive lipid, sphingosine-1-phosphate, and its variants, which moieties are capable of decreasing the effective concentration of bioactive lipid being targeted. In one embodiment, the immune-derived moiety is a humanized monoclonal antibody that is reactive against sphingosine-1-phosphate. | 2010-09-09 |
20100226917 | METHODS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES - The present invention discloses, in part, therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or B cell related tumors comprising the administration of a CHK1 inhibitor in combination with a B cell depleting antibody. The present invention further includes treating hematologic malignancies, including B cell lymphomas and leukemias, or B cell related tumors, which are resistant to cancer treatment comprising the administration of a CHK1 inhibitor. | 2010-09-09 |
20100226918 | PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS - The present invention relates to compounds of the formula I, | 2010-09-09 |
20100226919 | Antitumoral Treatments - The present invention relates to combinations of PM02734 with EGFR tyrosine kinase inhibitors, and the use of these combinations in the treatment of cancer. | 2010-09-09 |
20100226920 | MEDICAL DELIVERY DEVICE FOR THERAPEUTIC PROTEINS BASED ON SINGLE DOMAIN ANTIBODIES - The present invention relates to a pen-style administration device for administering therapeutic or diagnostic therapeutic proteins that are based on single domain antibodies, and methods of using such a device in therapies or diagnoses. | 2010-09-09 |
20100226921 | Methods for treating obesity using Fibroblast Growth Factor-Like Polypeptides - The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides. | 2010-09-09 |
20100226922 | SPECIFIC PROTEASE INHIBITORS AND THEIR USE IN CANCER THERAPY - The present invention relates to a pharmaceutical composition comprising at least one inhibitor of EpCAM cleavage and at least one anti-EpCAM antibody, the use of least one inhibitor of EpCAM cleavage and at least one anti-EpCAM antibody for the manufacture of a medicament for the treatment and/or prevention of cancer, an in vitro method of inhibiting cancer by inhibiting cleavage of EpCAM, the use of a TACE inhibitor and/or a presenilin-2 inhibitor for inhibiting EpCAM cleavage, and a method of identifying a compound useful as an anti-cancer agent. | 2010-09-09 |
20100226923 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 2010-09-09 |
20100226924 | CHIMERIC POLY PEPTIDES AND THE THERAPEUTIC USE THEREOF AGAINST A FLAVIVIRIDAE INFECTION - The invention relates to building a chimeric polypeptide used for preventing or treating a Flaviviridae infection. The use of the inventive chimeric polypeptide for producing recombinant viral vectors such as a measles living viral vector is also disclosed. | 2010-09-09 |
20100226925 | Homogeneous Antibody Populations - The present invention is generally directed to methods of producing an increase in the enrichment and/or recovery of preferred forms of monoclonal antibodies. More particularly, the invention relates to methods for eliminating disulfide heterogeneity in the hinge region of recombinant IgG2 antibody proteins. | 2010-09-09 |
20100226926 | Method of Detection of Fluorescence-Labeled Probes Attached to Diseased Solid Tissue - Disclosed herein, in certain embodiments, is a method of treating breast cancer characterized by the amplification of HER2 genes in a subject in need thereof, comprising: (a) isolating a tissue sample comprised of a plurality of breast tumor cells; (b) isolating a first section from said tissue sample; (c) isolating a second section from an adjacent portion of said tissue sample; (d) contacting the first section with a first stain; (e) contacting the second section with a probe; (f) imaging the first section following contact with the stain to produce a first image; (g) analyzing the first image for abnormal microscopic features; (h) identifying areas of interest in the first image that display abnormal microscopic features; (i) electronically annotating the first image to identify the areas of interest; (j) imaging the second section following contact with the probe; (k) aligning the first image and the second image; and (l) analyzing areas of interest in the second image that correspond to an area of interest identified in the first image; wherein the subject is administered an anti-HER2 antibody if HER2 is amplified or providing an alternative treatment if HER2 is not amplified. | 2010-09-09 |
20100226927 | SELECTIVE IMMUNODEPLETION OF ENDOGENOUS STEM CELL NICHE FOR ENGRAFTMENT - The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment and tolerance. | 2010-09-09 |
20100226928 | Lyophilised Antibody Formulation - Anti-sclerostin antibodies are formulated as lyophilisates. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 25 mg/ml. The lyophilisate may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid. | 2010-09-09 |
20100226929 | Direct Oxidation of Calcium/Calmodulin Dependent Protein Kinase II and Associated Diagnostic and Therapeutic Methods - Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy. | 2010-09-09 |
20100226930 | Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3 - The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders. | 2010-09-09 |
20100226931 | Compounds for immunopotentiation - Methods of stimulating an immune response and treating patients responsive thereto with 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, nucleoside analogs, and other small molecules are disclosed. In a preferred embodiment benzopyrimidine derivatives such as ZD-6474, MLN-518, lapatinib, gefitinib or erlotinib are used. | 2010-09-09 |
20100226932 | Adjuvant and Vaccine Compositions - Abstract Compositions comprising an emulsion and aluminum salt nano-/micro-particles surface stabilized with at least one surfactant are useful as immunological adjuvants. The emulsion of these compositions comprises at least one oil; at least one surfactant; a plurality of surfactant vesicles; optionally at least one sterol; and an aqueous phase. The present invention also provides vaccines comprising one or more antigens combined with the emulsion and surface stabilized aluminum salt particles of the present invention, or one or more antigens combined with non-ionic surfactant vesicles. | 2010-09-09 |
20100226933 | HYPOALLERGENIC PROTEINS - The present invention relates to a method for identifying a hypoallergenic derivative of a wild-type allergen comprising: determining the three-dimensional structure of a wild-type allergen; introducing at least one point mutation into said wild-type allergen, thereby obtaining a mutated allergen; identifying a hypoallergenic derivative of said wild-type allergen by detecting a destabilisation or change of the three-dimensional structure of the mutated allergen compared to the wild-type allergen by determining energy differences between the wild-type allergen and the mutant allergen expressed as a Z-score. | 2010-09-09 |
20100226934 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 2010-09-09 |
20100226935 | SYSTEM AND METHOD FOR ASSESSING TRADITIONAL MEDICINES - Methods of defining a standard for a traditional medicine are provided. A method can comprise obtaining at least two samples of the traditional medicine that have been authenticated by qualitative profiling as representing a control positive; quantitatively profiling each of the at least two samples using at least two physicochemical analyses; blending the at least two samples to form the standard; and creating a quantitative profile for the standard using at least two physicochemical analyses, wherein the quantitative profile for the standard defines the standard. Methods of certifying a test sample of a traditional medicine are also provided. A method can comprise creating a quantitative profile for the test sample using at least two physicochemical analyses; providing a standard; and comparing the quantitative profile for the standard to the quantitative profile for the test sample. A certified traditional medicine comprises a traditional medicine certified by these methods. | 2010-09-09 |
20100226936 | Plant Extract Compositions for Prevention and Treatment of Influenza - A composition for affecting one or more of influenza, inflammation, and immune system function, said composition comprising an extract prepared from | 2010-09-09 |
20100226937 | COMBINATION VACCINES WITH 1-HYDROXY-2-PHENOXYETHANE PRESERVATIVE - Processes for preparing combination vaccines that include diphtheria and tetanus toxoids, where these two toxoids are used in the processes as a single component containing both toxoids, and also containing 1-hydroxy-2-phenoxyethane. | 2010-09-09 |
20100226938 | Cellular and viral inactivation - The invention provides compositions of inactivated viruses, bacteria, fungi, parasites and tumor cells that can be used as vaccines. Methods for making such inactivated viruses, bacteria, fungi, parasites and tumor cells are also provided. | 2010-09-09 |
20100226939 | FORMULATIONS FOR PRESERVATION OF ROTAVIRUS - This invention provides formulations and methods for stabilizing viruses in liquid and dried formulations. In particular, formulations are provided including Zn | 2010-09-09 |
20100226940 | HERPES SIMPLEX VIRUS MUTANT ICP0 - A mutant herpesvirus that has a mutated gene that encodes a mutant infected cell protein 0 (ICP0) can be used in therapeutic methods as well as in diagnostics and research experiments. The encoded mutant ICP0 protein can be altered in one or more regions of ICP0 that are substantially conserved between two or more herpesviruses and/or within a phosphorylation region. The mutant herpesvirus can be substantially avirulent and immunogenic. | 2010-09-09 |
20100226941 | METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CPG OLIGONUCLEOTIDES - The present disclosure relates to a method of preventing or treating an infection caused by a bioterrorism agent, specifically to a method of increasing an immune response to a bioterrorism agent using an oligodeoxynucleotide including a CpG motif, and a method of enhancing the immunogenicity of a vaccine against a bioterrorism agent using an oligodeoxynucleotide including a CpG motif. | 2010-09-09 |
20100226942 | Producing an immune response for reducing the risk of developing brucellosis - This document relates to materials and methods for producing an immune response for reducing the risk of developing brucellosis. For example, this document provides vaccines for administration to animals as well as methods for producing an immune response against bacteria that cause brucellosis using vaccines provided herein. The vaccines provided herein can be effective for reducing the risk of developing brucellosis from multiple species of | 2010-09-09 |
20100226943 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL - Disclosed herein is an article that includes a first plurality of spaced features. The spaced features are arranged in a plurality of groupings; the groupings of features include repeat units; the spaced features within a grouping are spaced apart at an average distance of about 1 nanometer to about 500 micrometers; each feature having a surface that is substantially parallel to a surface on a neighboring feature; each feature being separated from its neighboring feature; the groupings of features being arranged with respect to one another so as to define a tortuous pathway. The plurality of spaced features provide the article with an engineered roughness index of about 5 to about 20. | 2010-09-09 |
20100226944 | PROCESS FOR THE PREPARATION OF CONTROLLED-RELEASE SOLID FORMULATIONS CONTAINING OXCARBAZEPINE, AND FORMULATIONS OBTAINABLE BY SAID PROCESS - The present invention relates to a process for the preparation of controlled-release solid oral pharmaceutical formulations of oxcarbazepine, and the pharmaceutical formulations obtainable by said process. | 2010-09-09 |
20100226945 | DYE-FREE PHARMACEUTICAL SUSPENSIONS AND RELATED METHODS - A dye-free pharmaceutical suspension having a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent having an average particle size of between about 10 and about 100 microns, an effective amount of non-reducing sweetener; an effective amount of water; and an effective amount of a suspending system; wherein the dye-free pharmaceutical suspension has a pH of from about 5 to about 6 and is substantially free of a reducing sugar and related methods. | 2010-09-09 |
20100226946 | Apparatus and Method for Producing Vitamin D in a Person - A kit for enhancing production of Vitamin D within a person's skin includes a source of Vitamin D, a sunlight exposure indicator, and a sunscreen. Vitamin D, for example, cod liver oil, is applied to the skin topically via a patch or towlette, or ingested orally. The exposure indicator is worn by the user and changes its state to indicate that the person has been exposed to sunlight for a predetermined period of time. The user preferably waits a sufficient time for the Vitamin D to be absorbed into the skin, and then exposes his or her skin to direct sunlight, and monitors the exposure indicator to determine if it has changed state. The user applies the sunscreen to the user's skin after the exposure indicator changes state. | 2010-09-09 |
20100226947 | ARTICLES OF MANUFACTURE RELEASING AN ACTIVE INGREDIENT - The present invention relates to articles of manufacture having a formulation distributed therein, wherein the formulation comprises an active agent which manifests a desirable property when released from the articles of manufacture. The present invention also relates to methods for manufacturing these articles of manufacture, to vehicles for applying the formulation to these articles of manufacture, and to perception indicators indicating the presence and the amount of formulation comprising an active agent applied to an article of manufacture. | 2010-09-09 |
20100226948 | METHODS AND COMPOSITIONS FOR TREATING ACNE - A method for treating acne on the skin. The method has the steps of (a) providing an drapeable or flexible porous article impregnated with an aqueous cleansing composition having a carrier, benzoyl peroxide, and one or more cleansing agents; (b) contacting an area of the skin affected by acne with the porous article such that the skin is contacted by the composition; and (c) removing the composition from the skin wherein residual benzoyl peroxide remains on the skin in an anti-acne effective amount. There are also anti-acne compositions. | 2010-09-09 |
20100226949 | INSECT REPELLENT AND ATTRACTANTS - The disclosure provides compounds useful as insect repellents and compositions comprising such repellents. The disclosure further provides insect traps. | 2010-09-09 |
20100226950 | MICROENCAPSULATED INSECTICIDE WITH ENHANCED RESIDUAL ACTIVITY - A method of formulating and using a microencapsulated insecticide with an extended field life after application of insecticidal activity. These methods include the steps of forming a microcapsule that includes at least one organophosphate insecticide and at least one non-volatile compound such as an esterified fatty acid that is at least partially surrounded by a polymer shell. These formulations can be used to control insect populations by singular or periodic applications of the microcapsule microencapsulated formulations to areas adjacent to insect populations. | 2010-09-09 |
20100226951 | METHODS AND COMPOSITIONS FOR CONTROLLING PLANT PESTS - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated delta-endotoxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:13-24, or the nucleotide sequence set forth in SEQ ID NO:1-12 and 25-44, as well as variants and fragments thereof. | 2010-09-09 |
20100226952 | DOMESTIC ANIMAL PARASITE-REPELLENT DEVICE - The present invention comprises a device for storing and releasing one or more mixed active compositions, for intensively controlling the external parasites of domestic animals, insects and other undesirable living organisms, composed of a polymer matrix comprising an ethylene/vinyl acetate copolymer blended with a polyether block amide, said polymer matrix being charged in an active composition/matrix ratio by weight of less than 0.66. A method for manufacturing such a device is also claimed. | 2010-09-09 |
20100226953 | MEDICAL DEVICES HAVING A COATING OF BIOLOGIC MACROMOLECULES - A medical device having a coating of biologic macromolecules. The coating of biologic macromolecules is protected by a temporary protective layer disposed over the biologic macromolecules. The temporary protective layer serves to protect the structure (e.g., conformation) and/or function (e.g., target binding capacity) of the biologic macromolecules during processing, storage, handling, and/or delivery (e.g., implantation or insertion into a patient) of the medical device. Upon implantation or insertion into a patient's body, the temporary protective layer may dissolve to expose the biologic macromolecules to the physiologic environment. | 2010-09-09 |
20100226954 | POLYMERIC DELIVERY FORMULATIONS OF LEUPROLIDE WITH IMPROVED EFFICACY - The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate. | 2010-09-09 |
20100226955 | POLYMER FOR CREATING HEMOCOMPATIBLE SURFACE - A polymer comprising a phosphoryl choline moiety(ies), a composition comprising the polymer and optionally a bioactive agent, an implantable device such as a DES or a non-implantable device such as an angioplasty balloon comprising thereon a coating comprising the polymer and optionally a bioactive agent, and a method of using the device for the treatment of a disorder in a human being are provided. | 2010-09-09 |
20100226956 | Production of moldable bone substitute - Composites and methods of producing a mouldable bone substitute are described. A scaffold for bone growth comprises nanocrystalline hydroxyapatite (HA), a bioresorbable plasticizer, and a biodegradable polymer. Plasticizers of the invention include oleic acid, tocopherol, eugenol, 1,2,3-triacetoxypropane, monoolein, and octyl-beta-D-glucopyranoside. Polymers of the invention include poly(caprolactone), poly(D,L-Lactic acid), and poly(glycolide-co lactide). Methods of regulating porosity, hardening speed, and shapeability are also described. Composites and methods are described using nanocrystalline HA produced with and without amino acids. The scaffold for bone growth described herein displays increased strength and shapeability. | 2010-09-09 |
20100226957 | Protein-Based Artificial Retinas - Multilayer protein films are provided, which comprise native bacteriorhodopsin and/or specialized bacteriorhodopsin mutants as the photoactive element. Also provided are artificial subretinal and epiretinal implants carrying such bacteriorhodopsin films, as well as methods for making and using the same, for example, to treat retinal diseases and conditions. | 2010-09-09 |
20100226958 | METHOD FOR MODIFYING THE WETTABILITY AND/OR OTHER BIOCOMPATIBILITY CHARACTERISTICS OF A SURFACE OF A BIOLOGICAL MATERIAL BY THE APPLICATION OF GAS CLUSTER ION BEAM TECHNOLOGY AND BIOLOGICAL MATERIALS MADE THEREBY - The invention provides a method for preparing a biological material for implanting. The invention also provides a biological material for surgical implantation. The invention further provides a biological composition for surgical implantation. | 2010-09-09 |
20100226959 | MATRIX THAT PROLONGS GROWTH FACTOR RELEASE - An implantable matrix is provided, the matrix having a porous interior configured to release a growth factor and to allow influx of at least progenitor, bone and/or cartilage cells therein; and a biodegradable membrane disposed on the porous interior, the biodegradable membrane being less porous than the porous interior and configured to retain the growth factor and release the growth factor from the porous interior as the biodegradable membrane degrades at or near the target tissue site. In some embodiments, a method for making the implantable collagen matrix is provided, the method comprising: providing a porous collagen layer configured to release a growth factor and to allow influx of at least progenitor, bone and/or cartilage cells therein, and disposing a collagen membrane on the porous collagen layer, the collagen membrane being less porous than the porous collagen layer and configured to retain the growth factor. | 2010-09-09 |
20100226960 | Natural biodegradable matrices and uses thereof - Matrices formed from a natural biodegradable material and that exhibit surface degradation in the presence of an enzyme are described. Matrices including a bioactive agent can be implanted or formed in a subject for release of the bioactive agent upon degradation of the matrix. The matrix can be provided in various forms, including coatings for implantable devices, implants, and in-situ formed matrices. The matrix can also be in the form of a medical device having a structure that is used to treat a medical condition. | 2010-09-09 |
20100226961 | CROSS-LINKED BIOACTIVE HYDROGEL MATRICES - The present invention is directed to a stabilized cross-linked hydrogel matrix comprising a first high molecular weight component and a second high molecular weight component that are covalently linked, and at least one stabilizing or enhancing agent, wherein the first high molecular weight component and the second high molecular weight component are each selected from the group consisting of polyglycans and polypeptides. This stabilized hydrogel matrix may be prepared as bioactive gels, pastes, slurries, cell attachment scaffolds for implantable medical devices, and casting or binding materials suitable for the construction of medical devices. The intrinsic bioactivity of the hydrogel matrix makes it useful as a gel or paste in multiple applications, including as a cell attachment scaffold that promotes wound healing around an implanted device, as gels and pastes for induction of localized vasculogenesis, wound healing, tissue repair, and regeneration, as a wound adhesive, and for tissue bulking. | 2010-09-09 |
20100226962 | PERI-CORNEAL DRUG DELIVERY DEVICE - The present invention is directed to an ophthalmic peri-corneal drug delivery device. The device includes a core of matrix material and therapeutic agent and a coating over the core. One or more opening[s] extend through the coating to provide for release of the drug to the eye. Moreover, the device is designed to lay atop the external surface of the eye. | 2010-09-09 |
20100226963 | BI-FUNCTIONAL CO-POLYMER USE FOR OPTHALMIC AND OTHER TOPICAL AND LOCAL APPLICATIONS - The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided. | 2010-09-09 |
20100226964 | Highly Compactable and durable direct compression excipients and excipient systems - The present invention relates to solid dispersions including, but not limited to, co-processed carbohydrates with different solubilities and concentrations, which have a microcrystalline plate structure. The solid dispersions, excipient systems and formulations of the present invention are highly compactable and durable and when compressed into solid dosage forms demonstrate uniform densification, low friability at low pressures, and/or relatively constant low disintegration times at various hardnesses. The solid dosage forms of the present invention demonstrate superior organoleptics, disintegration, and/or robustness. | 2010-09-09 |
20100226965 | COMPOSITIONS & METHODS FOR WOUND HEALING - The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osetoarthritic diseases, or diabetes). In particular, the present invention provides compositions and methods comprising molecules with linked α-gal epitopes for induction of an inflammatory response localized within or surrounding damaged tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects. | 2010-09-09 |
20100226966 | Method for transdermal controlled release drug delivery - Provided herein are dosing methods for administering a biologically active agent using microprojections and microprojection arrays. The microprojections may be coated with at least two layers in order to achieve sustained release of the agent into a patient's blood stream. One layer comprises a biologically active agent, for example, a PTH agent and optionally other excipients. Another layer, which is generally, initially devoid of active agent comprises a polymer or a mix of polymers to provide controlled release, for example sustained release, of the biologically active agent contained in the first layer. Microprojections coated with multiple layers, some layers containing a biologically active agent and other layers containing a polymer for controlled release are also contemplated herein. | 2010-09-09 |
20100226967 | IMAGING AND THERAPEUTIC METHOD USING PROGENITOR CELLS - The invention relates to a method of treating or diagnosing a disease state worsened by progenitor cells. The method utilizes a composition comprising a conjugate or complex of the general formula | 2010-09-09 |
20100226968 | Topical agent for muscle treatment - A topical liposomal base delivery agent for physiologically enhancing muscle efficiency and relaxation, which combines the physiological effects of guaifenesin, magnesium, and methylsulfonylmethane. The resulting physiological reaction reduces muscle and joint soreness in the host. The present invention is an improvement over existing methods that deliver magnesium to muscle tissue. | 2010-09-09 |
20100226969 | COMPOUNDS FOR INHIBITING PROTEIN AGGREGATION, AND METHODS FOR MAKING AND USING THEM - The invention provides compositions comprising protein aggregation inhibitors, and pharmaceutical compositions comprising them, and methods for making and using them, including methods for preventing, reversing, slowing or inhibiting protein aggregation, e.g., for treating diseases that are characterized by protein aggregation—including some degenerative neurological diseases such as Parkinson's disease. In one aspect, the compositions of the invention specifically target synuclein, beta-amyloid and/or tau protein aggregates, and the methods of the invention can be used to specifically prevent, reverse, slow or inhibit synuclein, beta-amyloid and/or tau protein aggregation. In alternative embodiments, the compositions and methods of the invention, are used to treat, prevent or ameliorate (including slowing the progression of) degenerative neurological diseases related to or caused by protein aggregation, e.g., synuclein, beta-amyloid and/or tau protein aggregation. In one aspect, compositions and methods of this invention are used to treat, prevent or ameliorate (including slowing the progression of) Parkinson's disease, Alzheimer's Disease (AD), Lewy body disease (LBD) and Multiple system atrophy (MSA). | 2010-09-09 |
20100226970 | Cationic liposome delivery of taxanes to angiogenic blood vessels - Angiogenic endothelial cells are selectively targeted with lipid/DNA complexes or cationic liposomes containing a substance which affects the targeted cells by inhibiting or promoting their growth. A site of angiogenesis can be precisely located by administering cationic liposomes containing a detectable label. The complexes may comprise nucleotide constructs which are comprised of promoters which are selectively and exclusively activated in the environment of an angiogenic endothelial cell. | 2010-09-09 |
20100226971 | ULTRASOUND-ENHANCED INTRASCLERAL DELIVERY OF MACROMOLECULES - The present invention provides a novel system and method for transscleral delivery of therapeutic agents, including macromolecules, into a target site in intrascleral space using ultrasound. Advantageously, the present invention not only significantly enhances transscleral diffusivity of macromolecular therapeutic agents, but also causes little damages to ocular tissues and structure. | 2010-09-09 |
20100226972 | TRANSDERMAL PAIN GEL - A transdermal gel including a complementary array of medicinal components has beneficial effects for pain relief in muscular and connective tissues. The medicinal components include active ingredients having a synergistic effect for permitting musculoskeletal movement by countering the symptoms of musculoskeletal pain and being non-narcotic for avoiding dependency, and are combined in a liposomal base with a wetting agent to form a gel consistency suitable for skin application. The transdermal gel allows topical application of greater quantities and concentrations of the active ingredients than could safely be obtained via conventional oral administration. | 2010-09-09 |
20100226973 | METHODS AND COMPOSITIONS FOR LIPOSOMAL FORMULATION OF ANTIGENS AND USES THEREOF - The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine (“DMPC”); either dimyristoylphosphatidylglycerol (“DMPG”) or dimyristoyltrimethylammonium propane (“DMTAP”) or both DMPC and DMTAP; and at least one sterol derivative providing a covalent anchor for one or more immunogenic polypeptide(s) or carbohydrate(s). | 2010-09-09 |
20100226974 | ANTIBODY RECOGNIZING ANTIGEN - The invention provides antibodies against a non-muscular myosin heavy chain type A or a mutant thereof, and F(ab′) | 2010-09-09 |
20100226975 | Compositions and Methods for Stabilizing Lipid Based Adjuvant Formulations Using Glycolipids - The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable. | 2010-09-09 |
20100226976 | ENCAPSULATED MESENCHYMAL STEM CELLS AND USES THEREOF - Provided is a composition-of-matter comprising a microcapsule encapsulating mesenchymal stem cells, wherein at least 97% of cells in said microcapsule are said mesenchymal stem cells. Also provided are methods of generating and using the composition-of-matter. | 2010-09-09 |
20100226977 | LOW VISCOSITY PHOSPHOLIPID COMPOSITIONS - The invention relates to processing crustaceans such as krill to oils comprising phospholipids that are Newtonian fluids and/or and have low viscosity, and in particular to the production of oils containing astaxanthin and phospholipids that show Newtonian fluidity and have a low viscosity. | 2010-09-09 |
20100226979 | Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate - Disclosed herein a taste masked pharmaceutical composition suitable for oral solid dosage form comprising adsorbate of unpleasant or objectionable tasting active pharmaceutical agents and water insoluble polymer, wherein said active is first blended with an adsorbent such as magnesium aluminium silicate to achieve partially or significantly taste masking of said active and further granulated the resultant blend with water insoluble polymer to strengthen the taste masking without affecting the release of said active. | 2010-09-09 |
20100226980 | NOVEL TABLET BASED ON S-ADENOSYL-METHIONINE - A subject of the invention is a tablet for pharmaceutical use, particularly for veterinary use, particularly suitable for the chronic treatment of hepatic insufficiency, comprising at least one S-Adenosyl-Methionine salt. Said tablet has the advantage of being divisible and being capable of including an appetizing agent. | 2010-09-09 |
20100226981 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A GABAPENTIN PRODRUG - Sustained release oral dosage forms with a high loading of a gabapentin prodrug are disclosed. | 2010-09-09 |
20100226982 | Stabilized Active Ingredient Composition - The invention relates to a stabilized active ingredient composition comprising at least one carrier material and at least one active ingredient present in stabilized form, and at least one agent for forming the active ingredient from the stabilized form upon addition of an aqueous phase to the composition, wherein the composition is obtained by freeze drying, a process for producing the composition as well as the use of the composition. | 2010-09-09 |
20100226983 | Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof - The present invention relates to methods for treating and preventing acne or | 2010-09-09 |
20100226984 | MOLECULAR RECOGNITION MATRIX AND METHOD FOR MAKING SAME - A molecular recognition matrix which utilizes the interaction between molecular building blocks and the surface of a substrate to develop specific molecular recognition cavities. | 2010-09-09 |
20100226985 | VISCOELASTIC AQUEOUS GELS COMPRISING MICROSPHERES - The present invention provides viscoelastic gel compositions comprising microparticles which are capable of interacting with each other in a non-ionic manner, thus forming a gel network. The gel compositions may incorporate active agents and provide controlled release of such agents. The compositions are useful as injectable depot formulations of therapeutic compounds. In a further aspect, microparticles capable of gel formation in an aqueous environment are provided, as well as method of making viscoelastic gels based on the interaction of uncharged microparticles. Moreover, the invention discloses kits for making viscoelastic gel compositions and uses thereof. | 2010-09-09 |
20100226986 | Therapeutic Particles Suitable for Parenteral Administration and Methods of Making and Using Same - Disclosed herein are therapeutic compositions for treating and preventing diseases such as neointimal hyperplasia (NIH), where the compositions comprise a therapeutic particle that has a localized association with a blood vessel and a therapeutic agent, such as an anti-NIH agent. Methods of use of the therapeutic compositions are also disclosed. | 2010-09-09 |
20100226987 | TARGETING CONJUGATES COMPRISING ACTIVE AGENTS ENCAPSULATED IN CYCLODEXTRIN-CONTAINING POLYMERS - A targeting conjugate is provided comprising an active agent, one or more residues of a cyclodextrin (CD)-containing polymer and a biorecognition molecule. The polymer is preferably a peptide or a polypeptide comprising at least one amino acid residue containing a functional side group to which at least one of the CD residues is linked covalently; the biorecognition molecule is covalently bonded directly or via a spacer to the polymer backbone of the CD-containing polymer; and the active agent is noncovalently encapsulated within the cavity of the cyclodextrin residues and/or entrapped within the polymer matrix of the CD-containing polymer. | 2010-09-09 |
20100226988 | CROSS-LINKING OF LOW-MOLECULAR WEIGHT AND HIGH-MOLECULAR WEIGHT POLYSACCHARIDES, PREPARATION OF INJECTABLE MONOPHASE HYDROGELS, POLYSACCHARIDES AND HYDROGELS OBTAINED - A process for the crosslinking of at least one polymer selected from polysaccharides and derivatives thereof, which is carried out in an aqueous solvent by the action of an effective and non-excessive amount of at least one crosslinking agent, characterized in that it is carried out on a mixture containing at least one low-molecular weight polymer and at least one high-molecular weight polymer. A process for the preparation of an injectable monophase hydrogel of at least one crosslinked polymer selected from polysaccharides and derivatives thereof. Crosslinked polymers and injectable monophase hydrogels respectively obtainable by each of said processes. | 2010-09-09 |
20100226989 | Nanoparticulate megestrol formulations - The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm. | 2010-09-09 |
20100226990 | Method of Producing Porous Microparticles - A method of preparing porous microparticles comprises the steps of combining one or more organic compounds with a volatile system, and drying the system thus formed to provide substantially pure porous microparticles of the organic compound or composite porous microparticles of combinations of organic compounds. Organic compounds used in the method may be one or more of a bioactive, a pharmaceutically acceptable excipient, a pharmaceutically acceptable adjuvant or combinations thereof. The invention also relates to porous microparticles produced by such a method, and pharmaceutical compositions comprising such porous microparticles. | 2010-09-09 |
20100226991 | SOLID INORGANIC/ORGANIC HYBRID WITH MODIFIED SURFACE - The invention relates to solid organometallic hybrids with modified surface. Said solid may be used for example for the encapsulation and vectoring of molecules of interest such as active pharmaceutical agents, compounds of interest in cosmetics and markers, for example, contrast agents. Said solids show good results in terms of loading capacity in medicament agents and in biocompatibility. | 2010-09-09 |
20100226992 | Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye - The present invention relates to development of efficacious pharmaceutical compositions in the form of intraocular suspensions comprising an anti-angiogenic compound in a therapeutically effective amount and a polyethylene glycol having a molecular weight of at least 2000, preferably at least 3000. | 2010-09-09 |
20100226993 | COMPOSITION FOR REGENERATIVE TREATMENT OF CARTILAGE DISEASE - A composition for regenerative treatment of cartilage disease, which comprises a PDE4 inhibitor as an active ingredient, specifically a composition comprising a PDE4 inhibitor and a biocompatible and biodegradable polymer is provided, which composition, when formulated into a form suited to administer locally to affected cartilage region, such as microsphere preparation, can provide a pharmaceutical composition showing an excellent effect in regenerative treatment of cartilage. | 2010-09-09 |
20100226994 | GRANULE, TABLET AND METHODS FOR PRODUCING THE SAME - A granule comprising a carrier composed of porous calcium silicate; a functional substance which is an oily liquid or a low-melting solid and a water-soluble antioxidizing agent, which are adsorbed on the carrier; and a granulating component. The problem to be solved is to improve storage stability of a powdered or tableted functional substance, for example, vitamin A to the level causing no problem in practical use. | 2010-09-09 |
20100226995 | MICROENCAPSULATED BIOACTIVE AGENTS FOR ORAL DELIVERY AND METHODS OF USE THEREOF - The presently claimed and disclosed inventive concept(s) contemplates a novel polymeric oral dosage form (transmucosal delivery vehicle) for delivery of pharmaceutical and nutriceutical bioactive agents to the mucosa and bloodstream of the intestine. The oral dosage form of the presently claimed and disclosed inventive concept(s) comprises a polymeric coating which encapsulates the bioactive agent and inhibits degradation and dissolution of the bioactive agent within the stomach and within the lumen of the intestine until after passing through the mucosal wall of the small and/or large intestine. The enzymatic degradation of the polymeric delivery vehicle containing the bioactive agent is substantially inhibited until after absorption of the polymeric delivery vehicle into blood vessels of the intestinal mucosa. It is a particular object of the presently claimed and disclosed inventive concept(s) to provide a new and improved method for enterically or intestinally encapsulating pharmaceutical and nutriceutical bioactive agent or agents for oral administration of the encapsulated bioactive agent or agents. | 2010-09-09 |
20100226996 | COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS - The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell. | 2010-09-09 |
20100226997 | CONTROLLED-RELEASE OPHTHALMIC VEHICLES - An ophthalmically acceptable vehicle includes an aqueous suspension having a first viscosity. The suspension includes about 0.1% to about 6.5% by weight of a carboxyl-containing polymer prepared by polymerizing one or more carboxyl-containing monoethylenically unsaturated monomers and less than about 5% by weight of a cross-linking agent. The polymer has average particle size of not more than about 50 μm in equivalent spherical diameter. The vehicle includes a second polymer that allows the carboxyl-containing polymer to remain suspended. Upon contact with tear fluid, the vehicle gels to a second viscosity which is greater than the first viscosity. A method of administering a medicament to the eye of a subject includes applying a composition that includes this ophthalmically acceptable vehicle and a medicament contained for treatment of a disease or disorder for which ophthalmic delivery is indicated. The medicament is released from the vehicle in a sustained release manner. | 2010-09-09 |
20100226998 | ANTI-VIRAL AND ANTI-MICROBIAL DENTAL OPERATIVE MATERIAL AND METHODS - An anti-microbial and/or anti-viral composition for use in disinfecting an oral tissue during a dental procedure includes at least one dental operative material that is allowed to contact the oral tissue for a period of time between about 2 seconds and about 1 month and an effective amount of an anti-viral and/or anti-bacterial agent included in or mixed with the dental operative material so as to impart an anti-bacterial and/or anti-viral effect at or near a site of administration in oral tissue. The anti-viral and/or anti-bacterial agent at least partially at least partially contributes to a two-log (or three-log, four-log, or five-log) reduction in viral and/or bacterial activity at or near a site of administration. The compositions protect a dental practitioner and/or other patient from being infected by a communicable disease carried by a treated patient. | 2010-09-09 |
20100226999 | PROCESS FOR FORMING STABILIZED OPHTHALMIC SOLUTIONS - The present invention relates to a method for forming an ophthalmic composition comprising mixing at least one hydroxide and pentetic acid with water and at least one oxidatively unstable component to form an ophthalmic composition comprising at least one salt of diethylenetriamine pentaacetic acid and a pH between about 6 and about 8. | 2010-09-09 |
20100227000 | MULTI-PART KIT SYSTEM FOR THE PREPARATION OF A DISINFECTANT OF THE PERACETIC ACID TYPE - A multi-part kit system comprising a solid part A which comprises at least one acetyl donor, a liquid part B in the form of an aqueous composition which comprises 3 to 35 wt. % of hydrogen peroxide and one or more parts C, wherein the solid part A and/or the part(s) C comprise at least one surfactant selected from the group consisting of anionic surfactants, amphoteric surfactants and nonionic surfactants, wherein the composition of the parts of the multi-part kit system is such, that directly after being mixed with each other and water in a specified ratio the pH of the mixture is in the range of 5.5 to 8. | 2010-09-09 |
20100227001 | METHOD OF DELIVERING NUTRIENTS - A method of delivering nutrients for bariatric patients comprising the sublingual administration of a B-complex vitamin composition and ingesting a liquid, water-soluble multi-vitamin complex orally at approximately the same time. The liquid multi-vitamin is comprised of a plurality of compounds from the group of Vitamin A, Vitamin C, Vitamin D and Vitamin E. After administering the Vitamin B complex and the liquid multi-vitamin, a solid vitamin formulation comprising at least two compounds from the group of iron, zinc, selenium, copper, chromium, Vitamin K, and manganese is ingested orally. A protein solution comprising proteins broken down into small peptide chains, calcium, and fiber may also be delivered orally to the bariatric patient in a liquid form. The method may be repeated once or twice daily. The method of the invention maximizes delivery and absorption of nutrients to the bariatric patient and the tolerance and speed of delivery. | 2010-09-09 |
20100227002 | ANTIOXIDANT COMPOSITIONS COMPRISING EXTRACTS OF MYRTLE AND ROSEMARY - The invention relates to a composition based on extracts of myrtle and rosemary which has been found to synergistically increase the protection of cells against pathophysiological conditions characterised and partly caused by overproduction of free radicals and to counteract the oxidative stress caused by excessive production of said free radicals, as well as for preventing and/or treating related pathologies, including apoptosis. | 2010-09-09 |
20100227003 | Self-Preserving Compositions - The invention provides self-preserving compositions and methods for their production. | 2010-09-09 |
20100227004 | OXIDATION METHOD AND COMPOSITIONS THEREFOR - The present invention generally relates to an improved two-part oxidizing system, as well as oxidizing compositions and methods for making and using the same, and in a particular embodiment to a two-part oxidizing system that, when mixed, yields an oxidizing composition. The two-part oxidizing system includes a metal chlorite first part, and an acid second part where the acid is sodium acid sulfate or a derivative thereof. | 2010-09-09 |
20100227005 | METHODS TO TREAT AND/OR PREVENT MUCOSITIS - The present invention relates to methods useful for treating and/or preventing mucositis using an active vitamin D compound. | 2010-09-09 |
20100227006 | POWDER MIX OF POTASSIUM CALCIUM CITRATE FOR THE TREATMENT OF KIDNEY STONES AND OSTEOPOROSIS - A composition comprising a powder mixture of potassium citrate and calcium citrate as mixtures of pure chemical salts and methods of making and using the composition are disclosed. The composition is useful for the treatment and prevention of kidney stones and osteoporosis and better delivers potassium and calcium than commonly used potassium and calcium supplements. | 2010-09-09 |
20100227007 | DIETARY SUPPLEMENTS CONTAINING EXTRACTS OF NELUMBO AND PROCESSES OF USING SAME - Materials derived from | 2010-09-09 |
20100227008 | SALICYLIC ACID ACNE SPRAY FORMULATIONS AND METHODS FOR TREATING ACNE WITH SAME - A fine mist spray of a salicylic acid solution is provided for treating body acne. The pH of the solution may be adjusted to above about 4.5 to reduce the incidence of nasal irritation and coughing due to incidental inhalation of the spray. | 2010-09-09 |